Full-Time

Global Brand Lead

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

70% in-office work model required.

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Market Research

You match the following Moderna's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Advanced degree (MBA, PharmD, or MD) required.
  • At least 12 years of progressive experience in biopharmaceutical marketing, commercialization, or related roles, with significant experience in product launch and lifecycle management.
  • Proven leadership experience, including managing high-performing teams and delivering results in a global, matrixed environment.
  • Strong expertise in developing global commercialization strategies, positioning, and patient campaigns.
  • Demonstrated ability to partner with regional and local teams to align global strategies and drive execution.
Responsibilities
  • Develop and lead the global commercialization strategy for Moderna’s RSV vaccine portfolio, ensuring alignment with Moderna’s vision, priorities, and market opportunities.
  • Drive strategic alignment across priority global markets, including the U.S., Europe, and key emerging regions.
  • Serve as the single point of accountability for launch readiness in key markets and provide launch support for top 10 markets as needed.
  • Partner with key global markets to co-create launch and commercialization strategies through regular strategy reviews, tailored resource development, and knowledge-sharing forums, ensuring successful execution in both pre-launch and post-launch phases.
  • Lead the development and delivery of global tools, campaigns, and resources, such as best practice playbooks and modular content, to empower local market success while maintaining consistency with global strategies.
  • Lead and provide direct launch support to key markets during critical phases to ensure readiness and adaptability.
  • Lead the development of global product positioning, messaging platforms, and core HCP and patient-facing materials for Moderna’s RSV vaccines.
  • Collaborate with regional and local teams to co-create impactful and tailored campaigns that reflect market needs and insights.
  • Build, lead, and inspire a high-performing global brand team, ensuring the team has the capabilities and mindset to drive success.
  • Foster a collaborative and agile culture, empowering team members to excel in a dynamic and fast-paced environment.
  • Partner closely with Clinical Development, Medical Affairs, Market Access/HEOR, CMC, and RWE teams to align on program strategies and key deliverables.
  • Serve as Commercial Lead on product development team ensuring key commercial input is provided at all stages of the development process to optimize commercial competitiveness.
  • Ensure effective input and collaboration with local and regional commercial teams to address market-specific opportunities and challenges.
  • Shape and drive lifecycle management strategies to maximize the long-term value of the RSV vaccine portfolio, including addressing age-specific needs (e.g., elderly, maternal, infant).
  • Identify opportunities for innovation, including market expansion, seasonal demand management, and competitive differentiation.
  • Leverage advanced analytics and market research to monitor market performance and inform adjustments to global and regional strategies.
  • Ensure robust feedback loops between global and local markets to address evolving dynamics and unmet patient and stakeholder needs.
Desired Qualifications
  • Experience in vaccines, with a strong preference for respiratory or RSV-specific products.
  • Strong cross-functional collaboration skills, particularly with Clinical, Medical Affairs, Market Access, and Regulatory teams.
  • Experience working across diverse cultural and regulatory environments.
  • Demonstrated ability to thrive in fast-paced, innovative environments, with a mindset focused on continuous learning and adaptability.
  • Proven ability to manage and influence senior stakeholders across geographies and functions.
  • Excellent strategic thinking, analytical, and project management skills, with a data-driven approach to decision-making.
  • Experience in managing global complexity and prioritizing in fast-paced, innovative environments.
  • Experience leveraging digital tools and platforms to enhance commercialization strategies.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial molecule that provides instructions for cells to produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially transform how drugs are discovered, developed, and manufactured. Unlike traditional pharmaceuticals, which often rely on proteins or small molecules, Moderna's mRNA-based therapies aim to instruct the body to produce its own therapeutic proteins. This unique method sets Moderna apart from competitors in the pharmaceutical industry. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of diseases.

Company Size

5,001-10,000

Company Stage

IPO

Total Funding

$6.5B

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna secured a $590 million contract for bird flu vaccine development.
  • The company is expanding its mRNA applications to rare diseases and cancer.
  • Moderna's cost reduction efforts aim to save nearly $1 billion by 2025.

What critics are saying

  • Increased competition from BioNTech and Pfizer may impact Moderna's market share.
  • Potential regulatory delays could affect Moderna's growth and revenue targets.
  • Fluctuating COVID-19 vaccine demand creates uncertainty in Moderna's sales forecasts.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has a strong late-stage pipeline with multiple product approvals anticipated.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

4%
PharmiWeb
Feb 14th, 2025
Moderna Reports Fourth Quarter And Fiscal Year 2024 Financial Results And Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S

The Scotsman
Feb 13th, 2025
Scotland's Life Sciences Conference & Awards 2025: Uniting industry leaders to shape the future

Scotland's thriving life sciences sector, a key driver of innovation and economic growth, is set to take centre stage in 2025 with the launch of Scotland's Life Sciences Conference, sponsored by Moderna.

PharmiWeb
Jan 29th, 2025
Moderna To Report Fourth Quarter And Full Year 2024 Financial Results On Friday, February 14, 2025

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines

PharmiWeb
Jan 24th, 2025
Moderna Awarded Tender For The Supply Of Its Mrna Covid-19 Vaccine In The European Union

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formatsCAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years."This agreement presents an opportunity for Moderna to support and strengthen national COVID-19 vaccination campaigns across participating countries," said Chantal Friebertshäuser, Senior Vice President, General Manager - Europe & Middle-East, Moderna. "Diversity of supply and availability of vaccine formats such as pre-filled syringes are vital to help increase vaccination rates and enhance vaccination campaign efficiency, ultimately strengthening health security."Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency.In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone

Managed Healthcare Executive
Jan 22nd, 2025
Moderna Awarded $590 Million for Bird Flu Vaccine Development

The development of avian influenza vaccines is the main priority amid rising cases in the United States.